These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
Aramark
|
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
20-8236097
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number)
|
2400 Market Street
Philadelphia, Pennsylvania
|
19103
|
(Address of principal executive offices)
|
(Zip Code)
|
Large accelerated filer
|
x
|
Accelerated filer
|
o
|
Non-accelerated filer
|
o
|
Smaller reporting company
|
o
|
Emerging growth company
|
o
|
TABLE OF CONTENTS
|
|||
|
|
|
Page
|
|
|||
|
|||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|||
|
|||
|
|||
|
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
|
|
December 28, 2018
|
|
September 28, 2018
|
||||
ASSETS
|
|
|
|
||||
Current Assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
249,881
|
|
|
$
|
215,025
|
|
Receivables (less allowances: 2019 - $51,399; 2018 - $52,682)
|
1,880,299
|
|
|
1,790,433
|
|
||
Inventories
|
371,111
|
|
|
724,802
|
|
||
Prepayments and other current assets
|
148,697
|
|
|
171,165
|
|
||
Total current assets
|
2,649,988
|
|
|
2,901,425
|
|
||
Property and Equipment, net
|
2,153,154
|
|
|
1,378,094
|
|
||
Goodwill
|
5,508,603
|
|
|
5,610,568
|
|
||
Other Intangible Assets
|
2,096,893
|
|
|
2,136,844
|
|
||
Other Assets
|
1,330,304
|
|
|
1,693,171
|
|
||
|
$
|
13,738,942
|
|
|
$
|
13,720,102
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
||||
Current Liabilities:
|
|
|
|
||||
Current maturities of long-term borrowings
|
$
|
53,441
|
|
|
$
|
30,907
|
|
Accounts payable
|
866,162
|
|
|
1,018,920
|
|
||
Accrued expenses and other current liabilities
|
1,277,672
|
|
|
1,440,332
|
|
||
Total current liabilities
|
2,197,275
|
|
|
2,490,159
|
|
||
Long-Term Borrowings
|
7,323,706
|
|
|
7,213,077
|
|
||
Deferred Income Taxes and Other Noncurrent Liabilities
|
990,021
|
|
|
977,215
|
|
||
Redeemable Noncontrolling Interest
|
10,047
|
|
|
10,093
|
|
||
Stockholders' Equity:
|
|
|
|
||||
Common stock, par value $.01 (authorized: 600,000,000 shares; issued: 2019—280,666,074 shares and 2018—279,314,297 shares;
and outstanding: 2019—245,883,193 shares and 2018—246,744,438 shares)
|
2,807
|
|
|
2,793
|
|
||
Capital surplus
|
3,154,479
|
|
|
3,132,421
|
|
||
Retained earnings
|
990,439
|
|
|
710,519
|
|
||
Accumulated other comprehensive loss
|
(132,996
|
)
|
|
(91,223
|
)
|
||
Treasury stock (shares held in treasury: 2019—34,782,881 shares and 2018—32,569,859 shares)
|
(796,836
|
)
|
|
(724,952
|
)
|
||
Total stockholders' equity
|
3,217,893
|
|
|
3,029,558
|
|
||
|
$
|
13,738,942
|
|
|
$
|
13,720,102
|
|
|
Three Months Ended
|
||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||
Revenue
|
$
|
4,265,349
|
|
|
$
|
3,965,118
|
|
Costs and Expenses:
|
|
|
|
||||
Cost of services provided
|
3,794,445
|
|
|
3,522,230
|
|
||
Depreciation and amortization
|
150,721
|
|
|
133,849
|
|
||
Selling and general corporate expenses
|
104,130
|
|
|
92,168
|
|
||
Gain on sale of Healthcare Technologies
|
(157,309
|
)
|
|
—
|
|
||
|
3,891,987
|
|
|
3,748,247
|
|
||
Operating income
|
373,362
|
|
|
216,871
|
|
||
Interest and Other Financing Costs, net
|
82,978
|
|
|
74,133
|
|
||
Income Before Income Taxes
|
290,384
|
|
|
142,738
|
|
||
(Benefit) Provision for Income Taxes
|
39,708
|
|
|
(149,702
|
)
|
||
Net income
|
250,676
|
|
|
292,440
|
|
||
Less: Net income (loss) attributable to noncontrolling interest
|
(6
|
)
|
|
156
|
|
||
Net income attributable to Aramark stockholders
|
$
|
250,682
|
|
|
$
|
292,284
|
|
|
|
|
|
||||
Earnings per share attributable to Aramark stockholders:
|
|
|
|
||||
Basic
|
$
|
1.02
|
|
|
$
|
1.19
|
|
Diluted
|
$
|
0.99
|
|
|
$
|
1.16
|
|
Weighted Average Shares Outstanding:
|
|
|
|
||||
Basic
|
246,887
|
|
|
245,086
|
|
||
Diluted
|
253,656
|
|
|
252,244
|
|
|
Three Months Ended
|
||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||
Net income
|
$
|
250,676
|
|
|
$
|
292,440
|
|
Other comprehensive income (loss), net of tax
|
|
|
|
||||
Pension plan adjustments
|
753
|
|
|
—
|
|
||
Foreign currency translation adjustments
|
(18,007
|
)
|
|
6,384
|
|
||
Fair value of cash flow hedges
|
(24,239
|
)
|
|
5,205
|
|
||
Share of equity investee's comprehensive income (loss)
|
(280
|
)
|
|
15
|
|
||
Other comprehensive income (loss), net of tax
|
(41,773
|
)
|
|
11,604
|
|
||
Comprehensive income
|
208,903
|
|
|
304,044
|
|
||
Less: Net income (loss) attributable to noncontrolling interest
|
(6
|
)
|
|
156
|
|
||
Comprehensive income attributable to Aramark stockholders
|
$
|
208,909
|
|
|
$
|
303,888
|
|
|
Three Months Ended
|
||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net income
|
$
|
250,676
|
|
|
$
|
292,440
|
|
Adjustments to reconcile net income to net cash used in operating activities
|
|
|
|
||||
Depreciation and amortization
|
150,721
|
|
|
133,849
|
|
||
Deferred income taxes
|
(5,764
|
)
|
|
(178,231
|
)
|
||
Share-based compensation expense
|
18,562
|
|
|
16,489
|
|
||
Net gain on sale of Healthcare Technologies
|
(140,165
|
)
|
|
—
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
||||
Accounts Receivable
|
(145,634
|
)
|
|
(121,828
|
)
|
||
Inventories
|
(7,858
|
)
|
|
(2,360
|
)
|
||
Prepayments and Other Current Assets
|
(47
|
)
|
|
4,321
|
|
||
Accounts Payable
|
(132,285
|
)
|
|
(127,343
|
)
|
||
Accrued Expenses
|
(150,229
|
)
|
|
(343,683
|
)
|
||
Other operating activities
|
(45,391
|
)
|
|
14,897
|
|
||
Net cash used in operating activities
|
(207,414
|
)
|
|
(311,449
|
)
|
||
Cash flows from investing activities:
|
|
|
|
||||
Purchases of property and equipment and other
|
(114,400
|
)
|
|
(118,907
|
)
|
||
Disposals of property and equipment
|
954
|
|
|
1,160
|
|
||
Proceeds from divestiture
|
293,711
|
|
|
—
|
|
||
Acquisition of certain businesses, net of cash acquired
|
(5,257
|
)
|
|
(1,321,688
|
)
|
||
Other investing activities
|
19,143
|
|
|
(3,351
|
)
|
||
Net cash provided by (used in) investing activities
|
194,151
|
|
|
(1,442,786
|
)
|
||
Cash flows from financing activities:
|
|
|
|
||||
Proceeds from long-term borrowings
|
72,723
|
|
|
2,279,287
|
|
||
Payments of long-term borrowings
|
(314,031
|
)
|
|
(647,622
|
)
|
||
Net change in funding under the Receivables Facility
|
390,000
|
|
|
136,050
|
|
||
Payments of dividends
|
(27,161
|
)
|
|
(25,779
|
)
|
||
Proceeds from issuance of common stock
|
1,077
|
|
|
4,929
|
|
||
Repurchase of stock
|
(50,000
|
)
|
|
(24,410
|
)
|
||
Other financing activities
|
(24,489
|
)
|
|
(21,354
|
)
|
||
Net cash provided by financing activities
|
48,119
|
|
|
1,701,101
|
|
||
Increase (decrease) in cash and cash equivalents
|
34,856
|
|
|
(53,134
|
)
|
||
Cash and cash equivalents, beginning of period
|
215,025
|
|
|
238,797
|
|
||
Cash and cash equivalents, end of period
|
$
|
249,881
|
|
|
$
|
185,663
|
|
|
|
Three Months Ended
|
||||||
(dollars in millions)
|
|
December 28, 2018
|
|
December 29, 2017
|
||||
Interest paid
|
|
$
|
80.2
|
|
|
$
|
69.3
|
|
Income taxes paid
|
|
$
|
57.7
|
|
|
$
|
63.2
|
|
|
Total
Stockholders'
Equity
|
|
Common
Stock |
|
Capital
Surplus |
|
Retained Earnings
|
|
Accumulated
Other
Comprehensive
Loss |
|
Treasury Stock
|
||||||||||||
Balance, September 28, 2018
|
$
|
3,029,558
|
|
|
$
|
2,793
|
|
|
$
|
3,132,421
|
|
|
$
|
710,519
|
|
|
$
|
(91,223
|
)
|
|
$
|
(724,952
|
)
|
Adoption of new accounting standard
|
58,395
|
|
|
|
|
|
|
58,395
|
|
|
|
|
|
||||||||||
Net income attributable to Aramark stockholders
|
250,682
|
|
|
|
|
|
|
250,682
|
|
|
|
|
|
||||||||||
Other comprehensive income (loss)
|
(41,773
|
)
|
|
|
|
|
|
|
|
(41,773
|
)
|
|
|
||||||||||
Capital contributions from issuance of common stock
|
3,510
|
|
|
14
|
|
|
3,496
|
|
|
|
|
|
|
|
|||||||||
Share-based compensation expense
|
18,562
|
|
|
|
|
18,562
|
|
|
|
|
|
|
|
||||||||||
Repurchases of Common Stock
|
(71,884
|
)
|
|
|
|
|
|
|
|
|
|
(71,884
|
)
|
||||||||||
Payments of dividends
|
(29,157
|
)
|
|
|
|
|
|
(29,157
|
)
|
|
|
|
|
||||||||||
Balance, December 28, 2018
|
$
|
3,217,893
|
|
|
$
|
2,807
|
|
|
$
|
3,154,479
|
|
|
$
|
990,439
|
|
|
$
|
(132,996
|
)
|
|
$
|
(796,836
|
)
|
|
Total
Stockholders' Equity |
|
Common
Stock |
|
Capital
Surplus |
|
Retained Earnings
|
|
Accumulated
Other Comprehensive Loss |
|
Treasury Stock
|
||||||||||||
Balance, September 29, 2017
|
$
|
2,459,061
|
|
|
$
|
2,771
|
|
|
$
|
3,014,546
|
|
|
$
|
247,050
|
|
|
$
|
(123,760
|
)
|
|
$
|
(681,546
|
)
|
Net income attributable to Aramark stockholders
|
292,284
|
|
|
|
|
|
|
292,284
|
|
|
|
|
|
||||||||||
Other comprehensive income (loss)
|
11,604
|
|
|
|
|
|
|
|
|
11,604
|
|
|
|
||||||||||
Capital contributions from issuance of common stock
|
8,499
|
|
|
11
|
|
|
8,488
|
|
|
|
|
|
|
|
|||||||||
Share-based compensation expense
|
16,489
|
|
|
|
|
16,489
|
|
|
|
|
|
|
|
||||||||||
Repurchases of Common Stock
|
(38,463
|
)
|
|
|
|
|
|
|
|
|
|
(38,463
|
)
|
||||||||||
Payments of dividends
|
(27,080
|
)
|
|
|
|
|
|
(27,080
|
)
|
|
|
|
|
||||||||||
Balance, December 29, 2017
|
$
|
2,722,394
|
|
|
$
|
2,782
|
|
|
$
|
3,039,523
|
|
|
$
|
512,254
|
|
|
$
|
(112,156
|
)
|
|
$
|
(720,009
|
)
|
|
Three Months Ended
|
||||||||||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||||||||||
|
Pre-Tax Amount
|
Tax Effect
|
After-Tax Amount
|
|
Pre-Tax Amount
|
Tax Effect
|
After-Tax Amount
|
||||||||
Net income
|
|
|
$
|
250,676
|
|
|
|
|
$
|
292,440
|
|
||||
Pension plan adjustments
|
753
|
|
—
|
|
753
|
|
|
—
|
|
—
|
|
—
|
|
||
Foreign currency translation adjustments
|
(17,876
|
)
|
(131
|
)
|
(18,007
|
)
|
|
6,384
|
|
—
|
|
6,384
|
|
||
Fair value of cash flow hedges
|
(32,702
|
)
|
8,463
|
|
(24,239
|
)
|
|
7,341
|
|
(2,136
|
)
|
5,205
|
|
||
Share of equity investee's comprehensive income (loss)
|
(280
|
)
|
—
|
|
(280
|
)
|
|
15
|
|
—
|
|
15
|
|
||
Other comprehensive income (loss)
|
(50,105
|
)
|
8,332
|
|
(41,773
|
)
|
|
13,740
|
|
(2,136
|
)
|
11,604
|
|
||
Comprehensive income
|
|
|
208,903
|
|
|
|
|
304,044
|
|
||||||
Less: Net income attributable to noncontrolling interest
|
|
|
(6
|
)
|
|
|
|
156
|
|
||||||
Comprehensive income attributable to Aramark stockholders
|
|
|
$
|
208,909
|
|
|
|
|
$
|
303,888
|
|
|
December 28, 2018
|
|
September 28, 2018
|
||||
Pension plan adjustments
|
$
|
(23,875
|
)
|
|
$
|
(24,628
|
)
|
Foreign currency translation adjustments
|
(111,818
|
)
|
|
(93,811
|
)
|
||
Cash flow hedges
|
11,953
|
|
|
36,192
|
|
||
Share of equity investee's accumulated other comprehensive loss
|
(9,256
|
)
|
|
(8,976
|
)
|
||
|
$
|
(132,996
|
)
|
|
$
|
(91,223
|
)
|
Current assets
|
$
|
237,807
|
|
Noncurrent assets
|
963,078
|
|
|
Total assets
|
$
|
1,200,885
|
|
|
|
||
Current liabilities
|
$
|
137,867
|
|
Noncurrent liabilities
|
67,590
|
|
|
Total liabilities
|
$
|
205,457
|
|
|
|
Estimated Fair
Value (in millions) |
|
Weighted-
Average Estimated Useful Life (in years) |
|||
Customer relationship assets
|
|
$
|
297.0
|
|
|
15
|
|
Trade names
|
|
|
24.0
|
|
|
3
|
to indefinite
|
Total intangible assets
|
|
$
|
321.0
|
|
|
|
Segment
|
September 28, 2018
|
|
Acquisitions and Divestitures
|
|
Translation
|
|
December 28, 2018
|
||||||||
FSS United States
|
$
|
4,028,454
|
|
|
$
|
(86,981
|
)
|
|
$
|
—
|
|
|
$
|
3,941,473
|
|
FSS International
|
626,379
|
|
|
—
|
|
|
(16,282
|
)
|
|
610,097
|
|
||||
Uniform
|
955,735
|
|
|
1,941
|
|
|
(643
|
)
|
|
957,033
|
|
||||
|
$
|
5,610,568
|
|
|
$
|
(85,040
|
)
|
|
$
|
(16,925
|
)
|
|
$
|
5,508,603
|
|
|
December 28, 2018
|
|
September 28, 2018
|
||||||||||||||||||||
|
Gross
Amount |
|
Accumulated
Amortization |
|
Net
Amount |
|
Gross
Amount |
|
Accumulated
Amortization |
|
Net
Amount |
||||||||||||
Customer relationship assets
|
$
|
2,201,474
|
|
|
$
|
(1,149,683
|
)
|
|
$
|
1,051,791
|
|
|
$
|
2,244,215
|
|
|
$
|
(1,156,811
|
)
|
|
$
|
1,087,404
|
|
Trade names
|
1,046,987
|
|
|
(1,885
|
)
|
|
1,045,102
|
|
|
1,050,825
|
|
|
(1,385
|
)
|
|
1,049,440
|
|
||||||
|
$
|
3,248,461
|
|
|
$
|
(1,151,568
|
)
|
|
$
|
2,096,893
|
|
|
$
|
3,295,040
|
|
|
$
|
(1,158,196
|
)
|
|
$
|
2,136,844
|
|
|
|
December 28, 2018
|
|
September 28, 2018
|
||||
Senior secured revolving credit facility, due October 2023
|
|
$
|
47,973
|
|
|
$
|
77,000
|
|
Senior secured term loan facility, due October 2023
|
|
520,568
|
|
|
538,674
|
|
||
Senior secured term loan facility, due March 2024
|
|
1,126,220
|
|
|
1,325,923
|
|
||
Senior secured term loan facility, due March 2025
|
|
1,657,192
|
|
|
1,656,919
|
|
||
5.125% senior notes, due January 2024
|
|
902,769
|
|
|
902,908
|
|
||
5.000% senior notes, due April 2025
|
|
591,179
|
|
|
590,884
|
|
||
3.125% senior notes, due April 2025
(1)
|
|
368,195
|
|
|
373,240
|
|
||
4.750% senior notes, due June 2026
|
|
494,241
|
|
|
494,082
|
|
||
5.000% senior notes, due February 2028
|
|
1,136,754
|
|
|
1,136,472
|
|
||
Receivables Facility, due May 2021
|
|
390,000
|
|
|
—
|
|
||
Capital leases
|
|
137,978
|
|
|
143,388
|
|
||
Other
|
|
4,078
|
|
|
4,494
|
|
||
|
|
7,377,147
|
|
|
7,243,984
|
|
||
Less—current portion
|
|
(53,441
|
)
|
|
(30,907
|
)
|
||
|
|
$
|
7,323,706
|
|
|
$
|
7,213,077
|
|
(1)
|
This is a Euro denominated borrowing.
|
|
Three Months Ended
|
||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||
Interest rate swap agreements
|
$
|
(31,000
|
)
|
|
$
|
5,245
|
|
|
|
Balance Sheet Location
|
|
December 28, 2018
|
|
September 28, 2018
|
||||
ASSETS
|
|
|
|
|
|
|
||||
Designated as hedging instruments:
|
|
|
|
|
|
|
||||
Interest rate swap agreements
|
|
Prepayments and other current assets
|
|
$
|
—
|
|
|
$
|
1,459
|
|
Interest rate swap agreements
|
|
Noncurrent Assets
|
|
$
|
24,355
|
|
|
$
|
54,708
|
|
|
|
|
|
|
|
|
||||
Not designated as hedging instruments:
|
|
|
|
|
|
|
||||
Foreign currency forward exchange contracts
|
|
Prepayments and other current assets
|
|
$
|
31
|
|
|
$
|
209
|
|
Gasoline and diesel fuel agreements
|
|
Prepayments and other current assets
|
|
$
|
—
|
|
|
$
|
3,623
|
|
|
|
|
|
$
|
24,386
|
|
|
$
|
59,999
|
|
LIABILITIES
|
|
|
|
|
|
|
||||
Designated as hedging instruments:
|
|
|
|
|
|
|
||||
Interest rate swap agreements
|
|
Other Noncurrent Liabilities
|
|
$
|
205
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
||||
Not designated as hedging instruments:
|
|
|
|
|
|
|
||||
Gasoline and diesel fuel agreements
|
|
Accounts payable
|
|
$
|
5,604
|
|
|
$
|
—
|
|
|
|
|
|
$
|
5,809
|
|
|
$
|
—
|
|
|
|
|
|
Three Months Ended
|
||||||
|
|
Income Statement Location
|
|
December 28, 2018
|
|
December 29, 2017
|
||||
Designated as hedging instruments:
|
|
|
|
|
|
|
||||
Interest rate swap agreements
|
|
Interest expense
|
|
$
|
(1,702
|
)
|
|
$
|
2,096
|
|
Not designated as hedging instruments:
|
|
|
|
|
|
|
||||
Gasoline and diesel fuel agreements
|
|
Costs of services provided / Selling and general corporate expenses
|
|
$
|
9,144
|
|
|
$
|
(3,416
|
)
|
Foreign currency forward exchange contracts
|
|
Interest expense
|
|
178
|
|
|
(650
|
)
|
||
|
|
|
|
9,322
|
|
|
(4,066
|
)
|
||
|
|
|
|
$
|
7,620
|
|
|
$
|
(1,970
|
)
|
•
|
costs to obtain contracts related to employee sales commissions, previously expensed to “Cost of services provided” at contract inception, are now capitalized in “Other Assets” (
$97.2 million
and
$100.7 million
as of September 29, 2018 and
December 28, 2018
, respectively);
|
•
|
certain fees within the Uniform segment,
$95.3 million
for the first quarter of fiscal
2019
, previously recognized as a reduction to “Cost of services provided,” are now recognized in “Revenue;”
|
•
|
client contract investments, previously capitalized within “Other Assets” and amortized to “Depreciation and amortization” will continue to be expensed over the contract life as either a leasehold improvement in “Property and equipment, net” (
$797.3 million
as of
December 28, 2018
) or as long-term prepaid rent or costs to fulfill in “Other Assets” (
$181.0 million
and
$116.3 million
as of
December 28, 2018
, respectively) and primarily classified in “Depreciation and amortization” or “Cost of services provided;” and
|
•
|
costs to fulfill contracts
related to personalized work apparel, linens and other rental items in service, previously capitalized within "Inventories" will now be capitalized within "Other Assets" (
$346.5 million
as of
December 28, 2018
).
|
|
|
December 28, 2018
|
||||||||||
|
|
As Reported
|
|
Adoption adjustments of ASC 606
|
|
Balances without adoption of ASC 606
|
||||||
ASSETS
|
|
|
|
|
|
|
||||||
Current Assets:
|
|
|
|
|
|
|
||||||
Cash and cash equivalents
|
|
$
|
249,881
|
|
|
$
|
—
|
|
|
$
|
249,881
|
|
Receivables, net
|
|
1,880,299
|
|
|
—
|
|
|
1,880,299
|
|
|||
Inventories
|
|
371,111
|
|
|
346,549
|
|
|
717,660
|
|
|||
Prepayments and other current assets
|
|
148,697
|
|
|
—
|
|
|
148,697
|
|
|||
Total current assets
|
|
2,649,988
|
|
|
346,549
|
|
|
2,996,537
|
|
|||
Property and Equipment, net
|
|
2,153,154
|
|
|
(797,262
|
)
|
|
1,355,892
|
|
|||
Goodwill
|
|
5,508,603
|
|
|
—
|
|
|
5,508,603
|
|
|||
Other Intangible Assets
|
|
2,096,893
|
|
|
—
|
|
|
2,096,893
|
|
|||
Other Assets
|
|
1,330,304
|
|
|
349,763
|
|
|
1,680,067
|
|
|||
|
|
$
|
13,738,942
|
|
|
$
|
(100,950
|
)
|
|
$
|
13,637,992
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
||||||
Current Liabilities:
|
|
|
|
|
|
|
||||||
Current maturities of long-term borrowings
|
|
$
|
53,441
|
|
|
$
|
—
|
|
|
$
|
53,441
|
|
Accounts payable
|
|
866,162
|
|
|
—
|
|
|
866,162
|
|
|||
Accrued expenses and other current liabilities
|
|
1,277,672
|
|
|
(23,526
|
)
|
|
1,254,146
|
|
|||
Total current liabilities
|
|
2,197,275
|
|
|
(23,526
|
)
|
|
2,173,749
|
|
|||
Long-Term Borrowings
|
|
7,323,706
|
|
|
—
|
|
|
7,323,706
|
|
|||
Deferred Income Taxes and Other Noncurrent Liabilities
|
|
990,021
|
|
|
(21,108
|
)
|
|
968,913
|
|
|||
Redeemable Noncontrolling Interest
|
|
10,047
|
|
|
—
|
|
|
10,047
|
|
|||
Stockholders' Equity:
|
|
|
|
|
|
|
||||||
Common stock
|
|
2,807
|
|
|
—
|
|
|
2,807
|
|
|||
Capital surplus
|
|
3,154,479
|
|
|
—
|
|
|
3,154,479
|
|
|||
Retained earnings
|
|
990,439
|
|
|
(56,316
|
)
|
|
934,123
|
|
|||
Accumulated other comprehensive loss
|
|
(132,996
|
)
|
|
—
|
|
|
(132,996
|
)
|
|||
Treasury stock
|
|
(796,836
|
)
|
|
—
|
|
|
(796,836
|
)
|
|||
Total stockholders' equity
|
|
3,217,893
|
|
|
(56,316
|
)
|
|
3,161,577
|
|
|||
|
|
$
|
13,738,942
|
|
|
$
|
(100,950
|
)
|
|
$
|
13,637,992
|
|
|
|
Three Months Ended December 28, 2018
|
||||||||||
|
|
As Reported
|
|
Adoption adjustments of ASC 606
|
|
Balances without adoption of ASC 606
|
||||||
|
|
|
|
|
|
|
||||||
Revenue
|
|
$
|
4,265,349
|
|
|
$
|
(88,507
|
)
|
|
$
|
4,176,842
|
|
Costs and Expenses:
|
|
|
|
|
|
|
||||||
Cost of services provided
|
|
3,794,445
|
|
|
(88,707
|
)
|
|
3,705,738
|
|
|||
Depreciation and amortization
|
|
150,721
|
|
|
3,006
|
|
|
153,727
|
|
|||
Selling and general corporate expenses
|
|
104,130
|
|
|
—
|
|
|
104,130
|
|
|||
Gain on sale of Healthcare Technologies
|
|
(157,309
|
)
|
|
—
|
|
|
(157,309
|
)
|
|||
|
|
3,891,987
|
|
|
(85,701
|
)
|
|
3,806,286
|
|
|||
Operating income
|
|
373,362
|
|
|
(2,806
|
)
|
|
370,556
|
|
|||
Interest and Other Financing Costs, net
|
|
82,978
|
|
|
—
|
|
|
82,978
|
|
|||
Income Before Income Taxes
|
|
290,384
|
|
|
(2,806
|
)
|
|
287,578
|
|
|||
(Benefit) Provision for Income Taxes
|
|
39,708
|
|
|
(727
|
)
|
|
38,981
|
|
|||
Net income
|
|
250,676
|
|
|
(2,079
|
)
|
|
248,597
|
|
|||
Less: Net income (loss) attributable to noncontrolling interest
|
|
(6
|
)
|
|
—
|
|
|
(6
|
)
|
|||
Net income attributable to Aramark stockholders
|
|
$
|
250,682
|
|
|
$
|
(2,079
|
)
|
|
$
|
248,603
|
|
|
|
Three Months Ended
|
||
|
|
December 28, 2018
|
||
FSS United States:
|
|
|
||
Business & Industry
|
|
$
|
399.9
|
|
Education
|
|
1,016.3
|
|
|
Healthcare
|
|
263.3
|
|
|
Sports, Leisure & Corrections
|
|
594.3
|
|
|
Facilities & Other
|
|
386.5
|
|
|
Total FSS United States
|
|
$
|
2,660.3
|
|
|
|
|
||
FSS International:
|
|
|
||
Europe
|
|
520.1
|
|
|
Rest of World
|
|
433.0
|
|
|
Total FSS International
|
|
$
|
953.1
|
|
|
|
|
||
Uniform
|
|
$
|
651.9
|
|
|
|
|
||
Total Revenue
|
|
$
|
4,265.3
|
|
|
|
Balance, September 28, 2018
|
|
Add: Net increase in current period deferred income
|
|
Less: Recognition of deferred income
|
|
Balance, December 28, 2018
|
||||||
Deferred income
|
|
$
|
281.5
|
|
|
155.3
|
|
|
(284.4
|
)
|
|
$
|
152.4
|
|
|
|
Three Months Ended
|
||||||
|
|
December 28, 2018
|
|
December 29, 2017
|
||||
TBOs
|
|
$
|
5.3
|
|
|
$
|
5.0
|
|
RSUs
|
|
8.9
|
|
|
5.8
|
|
||
PSUs
|
|
3.8
|
|
|
5.3
|
|
||
Deferred Stock and Other Units
|
|
0.6
|
|
|
0.4
|
|
||
|
|
$
|
18.6
|
|
|
$
|
16.5
|
|
|
|
|
|
|
||||
Taxes related to share-based compensation
|
|
$
|
4.6
|
|
|
$
|
4.6
|
|
|
|
Shares Granted (in millions)
|
|
Weighted-Average Grant-Date Fair Value (dollars per share)
|
|||
TBOs
|
|
1.8
|
|
|
$
|
8.36
|
|
RSUs
|
|
1.1
|
|
|
$
|
36.74
|
|
PSUs
(1)
|
|
1.2
|
|
|
$
|
36.74
|
|
|
|
4.1
|
|
|
|
(1)
|
Includes approximately 0.5 million shares resulting from the payout of the 2016 PSU grants due to exceeding the adjusted earnings per share target.
|
|
Three Months Ended
|
||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||
Earnings:
|
|
|
|
||||
Net income attributable to Aramark stockholders
|
$
|
250,682
|
|
|
$
|
292,284
|
|
Shares:
|
|
|
|
||||
Basic weighted-average shares outstanding
|
246,887
|
|
|
245,086
|
|
||
Effect of dilutive securities
|
6,769
|
|
|
7,158
|
|
||
Diluted weighted-average shares outstanding
|
253,656
|
|
|
252,244
|
|
||
|
|
|
|
||||
Basic Earnings Per Share:
|
|
|
|
||||
Net income attributable to Aramark stockholders
|
$
|
1.02
|
|
|
$
|
1.19
|
|
Diluted Earnings Per Share:
|
|
|
|
||||
Net income attributable to Aramark stockholders
|
$
|
0.99
|
|
|
$
|
1.16
|
|
|
Revenue
|
||||||
|
Three Months Ended
|
||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||
FSS United States
|
$
|
2,660.3
|
|
|
$
|
2,649.5
|
|
FSS International
|
953.1
|
|
|
913.0
|
|
||
Uniform
|
651.9
|
|
|
402.6
|
|
||
|
$
|
4,265.3
|
|
|
$
|
3,965.1
|
|
|
Operating Income
|
||||||
|
Three Months Ended
|
||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||
FSS United States
|
$
|
363.7
|
|
|
$
|
180.1
|
|
FSS International
|
11.5
|
|
|
43.9
|
|
||
Uniform
|
52.7
|
|
|
44.5
|
|
||
|
427.9
|
|
|
268.5
|
|
||
Corporate
|
(54.5
|
)
|
|
(51.6
|
)
|
||
Operating Income
|
373.4
|
|
|
216.9
|
|
||
Interest and Other Financing Costs, net
|
83.0
|
|
|
74.2
|
|
||
Income Before Income Taxes
|
$
|
290.4
|
|
|
$
|
142.7
|
|
•
|
Level 1—inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets
|
•
|
Level 2—inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument
|
•
|
Level 3—inputs to the valuation methodology are unobservable and significant to the fair value measurement
|
|
Aramark (Parent)
|
|
Issuers
|
|
Guarantors
|
|
Non
Guarantors |
|
Eliminations
|
|
Consolidated
|
||||||||||||
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Current Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cash and cash equivalents
|
$
|
5
|
|
|
$
|
46,068
|
|
|
$
|
31,036
|
|
|
$
|
172,772
|
|
|
$
|
—
|
|
|
$
|
249,881
|
|
Receivables
|
—
|
|
|
2,077
|
|
|
504,123
|
|
|
1,374,099
|
|
|
—
|
|
|
1,880,299
|
|
||||||
Inventories
|
—
|
|
|
15,710
|
|
|
236,659
|
|
|
118,742
|
|
|
—
|
|
|
371,111
|
|
||||||
Prepayments and other current assets
|
—
|
|
|
19,040
|
|
|
61,596
|
|
|
68,061
|
|
|
—
|
|
|
148,697
|
|
||||||
Total current assets
|
5
|
|
|
82,895
|
|
|
833,414
|
|
|
1,733,674
|
|
|
—
|
|
|
2,649,988
|
|
||||||
Property and Equipment, net
|
—
|
|
|
52,569
|
|
|
1,739,928
|
|
|
360,657
|
|
|
—
|
|
|
2,153,154
|
|
||||||
Goodwill
|
—
|
|
|
173,104
|
|
|
4,699,929
|
|
|
635,570
|
|
|
—
|
|
|
5,508,603
|
|
||||||
Investment in and Advances to Subsidiaries
|
3,217,888
|
|
|
7,192,089
|
|
|
—
|
|
|
764,712
|
|
|
(11,174,689
|
)
|
|
—
|
|
||||||
Other Intangible Assets
|
—
|
|
|
29,684
|
|
|
1,884,981
|
|
|
182,228
|
|
|
—
|
|
|
2,096,893
|
|
||||||
Other Assets
|
—
|
|
|
46,086
|
|
|
986,935
|
|
|
299,285
|
|
|
(2,002
|
)
|
|
1,330,304
|
|
||||||
|
$
|
3,217,893
|
|
|
$
|
7,576,427
|
|
|
$
|
10,145,187
|
|
|
$
|
3,976,126
|
|
|
$
|
(11,176,691
|
)
|
|
$
|
13,738,942
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Current Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Current maturities of long-term borrowings
|
$
|
—
|
|
|
$
|
3,673
|
|
|
$
|
27,648
|
|
|
$
|
22,120
|
|
|
$
|
—
|
|
|
$
|
53,441
|
|
Accounts payable
|
—
|
|
|
174,150
|
|
|
387,545
|
|
|
304,467
|
|
|
—
|
|
|
866,162
|
|
||||||
Accrued expenses and other current liabilities
|
—
|
|
|
232,306
|
|
|
684,373
|
|
|
360,905
|
|
|
88
|
|
|
1,277,672
|
|
||||||
Total current liabilities
|
—
|
|
|
410,129
|
|
|
1,099,566
|
|
|
687,492
|
|
|
88
|
|
|
2,197,275
|
|
||||||
Long-term Borrowings
|
—
|
|
|
6,368,256
|
|
|
75,566
|
|
|
879,884
|
|
|
—
|
|
|
7,323,706
|
|
||||||
Deferred Income Taxes and Other Noncurrent Liabilities
|
—
|
|
|
418,957
|
|
|
500,138
|
|
|
70,926
|
|
|
—
|
|
|
990,021
|
|
||||||
Intercompany Payable
|
—
|
|
|
—
|
|
|
4,946,829
|
|
|
631,565
|
|
|
(5,578,394
|
)
|
|
—
|
|
||||||
Redeemable Noncontrolling Interest
|
—
|
|
|
—
|
|
|
10,047
|
|
|
—
|
|
|
—
|
|
|
10,047
|
|
||||||
Total Stockholders' Equity
|
3,217,893
|
|
|
379,085
|
|
|
3,513,041
|
|
|
1,706,259
|
|
|
(5,598,385
|
)
|
|
3,217,893
|
|
||||||
|
$
|
3,217,893
|
|
|
$
|
7,576,427
|
|
|
$
|
10,145,187
|
|
|
$
|
3,976,126
|
|
|
$
|
(11,176,691
|
)
|
|
$
|
13,738,942
|
|
|
Aramark (Parent)
|
|
Issuers
|
|
Guarantors
|
|
Non
Guarantors |
|
Eliminations
|
|
Consolidated
|
||||||||||||
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Current Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cash and cash equivalents
|
$
|
5
|
|
|
$
|
50,716
|
|
|
$
|
29,844
|
|
|
$
|
134,460
|
|
|
$
|
—
|
|
|
$
|
215,025
|
|
Receivables
|
—
|
|
|
1,038
|
|
|
443,599
|
|
|
1,345,796
|
|
|
—
|
|
|
1,790,433
|
|
||||||
Inventories
|
—
|
|
|
15,857
|
|
|
592,259
|
|
|
116,686
|
|
|
—
|
|
|
724,802
|
|
||||||
Prepayments and other current assets
|
—
|
|
|
21,411
|
|
|
86,100
|
|
|
63,654
|
|
|
—
|
|
|
171,165
|
|
||||||
Total current assets
|
5
|
|
|
89,022
|
|
|
1,151,802
|
|
|
1,660,596
|
|
|
—
|
|
|
2,901,425
|
|
||||||
Property and Equipment, net
|
—
|
|
|
28,341
|
|
|
1,013,523
|
|
|
336,230
|
|
|
—
|
|
|
1,378,094
|
|
||||||
Goodwill
|
—
|
|
|
173,104
|
|
|
4,783,547
|
|
|
653,917
|
|
|
—
|
|
|
5,610,568
|
|
||||||
Investment in and Advances to Subsidiaries
|
3,029,553
|
|
|
7,441,605
|
|
|
90,049
|
|
|
844,245
|
|
|
(11,405,452
|
)
|
|
—
|
|
||||||
Other Intangible Assets
|
—
|
|
|
29,684
|
|
|
1,919,795
|
|
|
187,365
|
|
|
—
|
|
|
2,136,844
|
|
||||||
Other Assets
|
—
|
|
|
100,754
|
|
|
1,264,976
|
|
|
329,443
|
|
|
(2,002
|
)
|
|
1,693,171
|
|
||||||
|
$
|
3,029,558
|
|
|
$
|
7,862,510
|
|
|
$
|
10,223,692
|
|
|
$
|
4,011,796
|
|
|
$
|
(11,407,454
|
)
|
|
$
|
13,720,102
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Current Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Current maturities of long-term borrowings
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
26,564
|
|
|
$
|
4,343
|
|
|
$
|
—
|
|
|
$
|
30,907
|
|
Accounts payable
|
—
|
|
|
128,460
|
|
|
483,606
|
|
|
406,854
|
|
|
—
|
|
|
1,018,920
|
|
||||||
Accrued expenses and other current liabilities
|
—
|
|
|
205,807
|
|
|
926,794
|
|
|
307,643
|
|
|
88
|
|
|
1,440,332
|
|
||||||
Total current liabilities
|
—
|
|
|
334,267
|
|
|
1,436,964
|
|
|
718,840
|
|
|
88
|
|
|
2,490,159
|
|
||||||
Long-term Borrowings
|
—
|
|
|
6,651,110
|
|
|
82,097
|
|
|
479,870
|
|
|
—
|
|
|
7,213,077
|
|
||||||
Deferred Income Taxes and Other Noncurrent Liabilities
|
—
|
|
|
432,583
|
|
|
466,331
|
|
|
78,301
|
|
|
—
|
|
|
977,215
|
|
||||||
Intercompany Payable
|
—
|
|
|
—
|
|
|
4,827,084
|
|
|
955,407
|
|
|
(5,782,491
|
)
|
|
—
|
|
||||||
Redeemable Noncontrolling Interest
|
—
|
|
|
—
|
|
|
10,093
|
|
|
—
|
|
|
—
|
|
|
10,093
|
|
||||||
Total Stockholders' Equity
|
3,029,558
|
|
|
444,550
|
|
|
3,401,123
|
|
|
1,779,378
|
|
|
(5,625,051
|
)
|
|
3,029,558
|
|
||||||
|
$
|
3,029,558
|
|
|
$
|
7,862,510
|
|
|
$
|
10,223,692
|
|
|
$
|
4,011,796
|
|
|
$
|
(11,407,454
|
)
|
|
$
|
13,720,102
|
|
|
Aramark (Parent)
|
|
Issuers
|
|
Guarantors
|
|
Non
Guarantors |
|
Eliminations
|
|
Consolidated
|
||||||||||||
Revenue
|
$
|
—
|
|
|
$
|
268,522
|
|
|
$
|
2,848,927
|
|
|
$
|
1,147,900
|
|
|
$
|
—
|
|
|
$
|
4,265,349
|
|
Costs and Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cost of services provided
|
—
|
|
|
246,609
|
|
|
2,464,602
|
|
|
1,083,234
|
|
|
—
|
|
|
3,794,445
|
|
||||||
Depreciation and amortization
|
—
|
|
|
4,472
|
|
|
120,982
|
|
|
25,267
|
|
|
—
|
|
|
150,721
|
|
||||||
Selling and general corporate expenses
|
—
|
|
|
55,742
|
|
|
41,552
|
|
|
6,836
|
|
|
—
|
|
|
104,130
|
|
||||||
Gain on sale of Healthcare Technologies
|
—
|
|
|
—
|
|
|
(157,309
|
)
|
|
—
|
|
|
—
|
|
|
(157,309
|
)
|
||||||
Interest and other financing costs, net
|
—
|
|
|
78,560
|
|
|
971
|
|
|
3,447
|
|
|
—
|
|
|
82,978
|
|
||||||
Expense allocations
|
—
|
|
|
(230,589
|
)
|
|
225,801
|
|
|
4,788
|
|
|
—
|
|
|
—
|
|
||||||
|
—
|
|
|
154,794
|
|
|
2,696,599
|
|
|
1,123,572
|
|
|
—
|
|
|
3,974,965
|
|
||||||
Income before Income Taxes
|
—
|
|
|
113,728
|
|
|
152,328
|
|
|
24,328
|
|
|
—
|
|
|
290,384
|
|
||||||
Provision for Income Taxes
|
—
|
|
|
8,741
|
|
|
25,000
|
|
|
5,967
|
|
|
—
|
|
|
39,708
|
|
||||||
Equity in Net Income of Subsidiaries
|
250,682
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(250,682
|
)
|
|
—
|
|
||||||
Net income
|
250,682
|
|
|
104,987
|
|
|
127,328
|
|
|
18,361
|
|
|
(250,682
|
)
|
|
250,676
|
|
||||||
Less: Net income (loss) attributable to noncontrolling interest
|
—
|
|
|
—
|
|
|
(6
|
)
|
|
—
|
|
|
—
|
|
|
(6
|
)
|
||||||
Net income attributable to Aramark stockholders
|
250,682
|
|
|
104,987
|
|
|
127,334
|
|
|
18,361
|
|
|
(250,682
|
)
|
|
250,682
|
|
||||||
Other comprehensive income (loss), net of tax
|
(41,773
|
)
|
|
(27,351
|
)
|
|
—
|
|
|
(44,951
|
)
|
|
72,302
|
|
|
(41,773
|
)
|
||||||
Comprehensive income (loss) attributable to Aramark stockholders
|
$
|
208,909
|
|
|
$
|
77,636
|
|
|
$
|
127,334
|
|
|
$
|
(26,590
|
)
|
|
$
|
(178,380
|
)
|
|
$
|
208,909
|
|
|
Aramark (Parent)
|
|
Issuers
|
|
Guarantors
|
|
Non Guarantors
|
|
Eliminations
|
|
Consolidated
|
||||||||||||
Revenue
|
$
|
—
|
|
|
$
|
258,271
|
|
|
$
|
2,643,266
|
|
|
$
|
1,063,581
|
|
|
$
|
—
|
|
|
$
|
3,965,118
|
|
Costs and Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cost of services provided
|
—
|
|
|
225,216
|
|
|
2,320,190
|
|
|
976,824
|
|
|
—
|
|
|
3,522,230
|
|
||||||
Depreciation and amortization
|
—
|
|
|
4,491
|
|
|
105,895
|
|
|
23,463
|
|
|
—
|
|
|
133,849
|
|
||||||
Selling and general corporate expenses
|
—
|
|
|
53,666
|
|
|
33,698
|
|
|
4,804
|
|
|
—
|
|
|
92,168
|
|
||||||
Interest and other financing costs
|
—
|
|
|
71,175
|
|
|
68
|
|
|
2,890
|
|
|
—
|
|
|
74,133
|
|
||||||
Expense allocations
|
—
|
|
|
(65,203
|
)
|
|
61,110
|
|
|
4,093
|
|
|
—
|
|
|
—
|
|
||||||
|
—
|
|
|
289,345
|
|
|
2,520,961
|
|
|
1,012,074
|
|
|
—
|
|
|
3,822,380
|
|
||||||
Income (Loss) before Income Tax
|
—
|
|
|
(31,074
|
)
|
|
122,305
|
|
|
51,507
|
|
|
—
|
|
|
142,738
|
|
||||||
Provision (Benefit) for Income Taxes
|
—
|
|
|
(20,709
|
)
|
|
(142,447
|
)
|
|
13,454
|
|
|
—
|
|
|
(149,702
|
)
|
||||||
Equity in Net Income of Subsidiaries
|
292,284
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(292,284
|
)
|
|
—
|
|
||||||
Net income (loss)
|
292,284
|
|
|
(10,365
|
)
|
|
264,752
|
|
|
38,053
|
|
|
(292,284
|
)
|
|
292,440
|
|
||||||
Less: Net income attributable to noncontrolling interest
|
—
|
|
|
—
|
|
|
156
|
|
|
—
|
|
|
—
|
|
|
156
|
|
||||||
Net income (loss) attributable to Aramark stockholders
|
292,284
|
|
|
(10,365
|
)
|
|
264,596
|
|
|
38,053
|
|
|
(292,284
|
)
|
|
292,284
|
|
||||||
Other comprehensive income, net of tax
|
11,604
|
|
|
5,389
|
|
|
—
|
|
|
19,002
|
|
|
(24,391
|
)
|
|
11,604
|
|
||||||
Comprehensive income (loss) attributable to Aramark stockholders
|
$
|
303,888
|
|
|
$
|
(4,976
|
)
|
|
$
|
264,596
|
|
|
$
|
57,055
|
|
|
$
|
(316,675
|
)
|
|
$
|
303,888
|
|
|
Aramark (Parent)
|
|
Issuers
|
|
Guarantors
|
|
Non
Guarantors |
|
Eliminations
|
|
Consolidated
|
||||||||||||
Net cash provided by (used in) operating activities
|
$
|
—
|
|
|
$
|
172,881
|
|
|
$
|
(328,363
|
)
|
|
$
|
(47,432
|
)
|
|
$
|
(4,500
|
)
|
|
$
|
(207,414
|
)
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Purchases of property and equipment and other assets
|
—
|
|
|
(4,454
|
)
|
|
(89,443
|
)
|
|
(20,503
|
)
|
|
—
|
|
|
(114,400
|
)
|
||||||
Disposals of property and equipment
|
—
|
|
|
50
|
|
|
564
|
|
|
340
|
|
|
—
|
|
|
954
|
|
||||||
Proceeds from divestiture
|
—
|
|
|
—
|
|
|
293,711
|
|
|
—
|
|
|
—
|
|
|
293,711
|
|
||||||
Acquisitions of businesses, net of cash acquired
|
—
|
|
|
—
|
|
|
(5,033
|
)
|
|
(224
|
)
|
|
—
|
|
|
(5,257
|
)
|
||||||
Other investing activities
|
—
|
|
|
862
|
|
|
17,944
|
|
|
337
|
|
|
—
|
|
|
19,143
|
|
||||||
Net cash provided by (used in) investing activities
|
—
|
|
|
(3,542
|
)
|
|
217,743
|
|
|
(20,050
|
)
|
|
—
|
|
|
194,151
|
|
||||||
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Proceeds from long-term borrowings
|
—
|
|
|
—
|
|
|
—
|
|
|
72,723
|
|
|
—
|
|
|
72,723
|
|
||||||
Payments of long-term borrowings
|
—
|
|
|
(278,339
|
)
|
|
(8,781
|
)
|
|
(26,911
|
)
|
|
—
|
|
|
(314,031
|
)
|
||||||
Net change in funding under the Receivables Facility
|
—
|
|
|
—
|
|
|
—
|
|
|
390,000
|
|
|
—
|
|
|
390,000
|
|
||||||
Payments of dividends
|
—
|
|
|
(27,161
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(27,161
|
)
|
||||||
Proceeds from issuance of common stock
|
—
|
|
|
1,077
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,077
|
|
||||||
Repurchase of stock
|
—
|
|
|
(50,000
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(50,000
|
)
|
||||||
Other financing activities
|
—
|
|
|
(23,447
|
)
|
|
(929
|
)
|
|
(113
|
)
|
|
—
|
|
|
(24,489
|
)
|
||||||
Change in intercompany, net
|
—
|
|
|
203,883
|
|
|
121,522
|
|
|
(329,905
|
)
|
|
4,500
|
|
|
—
|
|
||||||
Net cash provided by (used in) financing activities
|
—
|
|
|
(173,987
|
)
|
|
111,812
|
|
|
105,794
|
|
|
4,500
|
|
|
48,119
|
|
||||||
Increase (decrease) in cash and cash equivalents
|
—
|
|
|
(4,648
|
)
|
|
1,192
|
|
|
38,312
|
|
|
—
|
|
|
34,856
|
|
||||||
Cash and cash equivalents, beginning of period
|
5
|
|
|
50,716
|
|
|
29,844
|
|
|
134,460
|
|
|
—
|
|
|
215,025
|
|
||||||
Cash and cash equivalents, end of period
|
$
|
5
|
|
|
$
|
46,068
|
|
|
$
|
31,036
|
|
|
$
|
172,772
|
|
|
$
|
—
|
|
|
$
|
249,881
|
|
|
Aramark (Parent)
|
|
Issuers
|
|
Guarantors
|
|
Non
Guarantors |
|
Eliminations
|
|
Consolidated
|
||||||||||||
Net cash used in operating activities
|
$
|
—
|
|
|
$
|
(63,662
|
)
|
|
$
|
(191,802
|
)
|
|
$
|
(20,982
|
)
|
|
$
|
(35,003
|
)
|
|
$
|
(311,449
|
)
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Purchases of property and equipment and other assets
|
—
|
|
|
(2,166
|
)
|
|
(101,674
|
)
|
|
(15,067
|
)
|
|
—
|
|
|
(118,907
|
)
|
||||||
Disposals of property and equipment
|
—
|
|
|
112
|
|
|
515
|
|
|
533
|
|
|
—
|
|
|
1,160
|
|
||||||
Acquisitions of businesses, net of cash acquired
|
—
|
|
|
(1,386,378
|
)
|
|
(22,565
|
)
|
|
87,255
|
|
|
—
|
|
|
(1,321,688
|
)
|
||||||
Other investing activities
|
—
|
|
|
342
|
|
|
(61
|
)
|
|
(3,632
|
)
|
|
—
|
|
|
(3,351
|
)
|
||||||
Net cash (used in) provided by investing activities
|
—
|
|
|
(1,388,090
|
)
|
|
(123,785
|
)
|
|
69,089
|
|
|
—
|
|
|
(1,442,786
|
)
|
||||||
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Proceeds from long-term borrowings
|
—
|
|
|
2,270,600
|
|
|
—
|
|
|
8,687
|
|
|
—
|
|
|
2,279,287
|
|
||||||
Payments of long-term borrowings
|
—
|
|
|
(633,997
|
)
|
|
(4,672
|
)
|
|
(8,953
|
)
|
|
—
|
|
|
(647,622
|
)
|
||||||
Net change in funding under the Receivables Facility
|
—
|
|
|
—
|
|
|
—
|
|
|
136,050
|
|
|
—
|
|
|
136,050
|
|
||||||
Payments of dividends
|
—
|
|
|
(25,779
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(25,779
|
)
|
||||||
Proceeds from issuance of common stock
|
—
|
|
|
4,929
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4,929
|
|
||||||
Repurchase of stock
|
—
|
|
|
(24,410
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(24,410
|
)
|
||||||
Other financing activities
|
—
|
|
|
(20,859
|
)
|
|
(495
|
)
|
|
—
|
|
|
—
|
|
|
(21,354
|
)
|
||||||
Change in intercompany, net
|
—
|
|
|
(194,568
|
)
|
|
318,705
|
|
|
(159,140
|
)
|
|
35,003
|
|
|
—
|
|
||||||
Net cash provided by (used in) financing activities
|
—
|
|
|
1,375,916
|
|
|
313,538
|
|
|
(23,356
|
)
|
|
35,003
|
|
|
1,701,101
|
|
||||||
Increase (decrease) in cash and cash equivalents
|
—
|
|
|
(75,836
|
)
|
|
(2,049
|
)
|
|
24,751
|
|
|
—
|
|
|
(53,134
|
)
|
||||||
Cash and cash equivalents, beginning of period
|
5
|
|
|
111,512
|
|
|
37,513
|
|
|
89,767
|
|
|
—
|
|
|
238,797
|
|
||||||
Cash and cash equivalents, end of period
|
$
|
5
|
|
|
$
|
35,676
|
|
|
$
|
35,464
|
|
|
$
|
114,518
|
|
|
$
|
—
|
|
|
$
|
185,663
|
|
|
Three Months Ended
|
|
Change
|
|||||||||||
|
December 28, 2018
|
|
December 29, 2017
|
|
$
|
|
%
|
|||||||
Revenue
|
$
|
4,265.3
|
|
|
$
|
3,965.1
|
|
|
$
|
300.2
|
|
|
8
|
%
|
Costs and Expenses:
|
|
|
|
|
|
|
|
|||||||
Cost of services provided
|
3,794.4
|
|
|
3,522.3
|
|
|
272.1
|
|
|
8
|
%
|
|||
Other operating expenses
|
97.5
|
|
|
225.9
|
|
|
(128.4
|
)
|
|
(57
|
)%
|
|||
Gain on sale of Healthcare Technologies
|
157.3
|
|
|
—
|
|
|
157.3
|
|
|
100
|
%
|
|||
|
4,049.2
|
|
|
3,748.2
|
|
|
301.0
|
|
|
8
|
%
|
|||
Operating income
|
373.4
|
|
|
216.9
|
|
|
156.5
|
|
|
72
|
%
|
|||
Interest and Other Financing Costs, net
|
83.0
|
|
|
74.2
|
|
|
8.8
|
|
|
12
|
%
|
|||
Income Before Income Taxes
|
290.4
|
|
|
142.7
|
|
|
147.7
|
|
|
104
|
%
|
|||
(Benefit) Provision for Income Taxes
|
39.7
|
|
|
(149.7
|
)
|
|
189.4
|
|
|
(127
|
)%
|
|||
Net income
|
$
|
250.7
|
|
|
$
|
292.4
|
|
|
$
|
(41.7
|
)
|
|
(14
|
)%
|
|
|
Three Months Ended
|
|
Change
|
|||||||||||
Revenue by Segment
(1)
|
|
December 28, 2018
|
|
December 29, 2017
|
|
$
|
|
%
|
|||||||
FSS United States
|
|
$
|
2,660.3
|
|
|
$
|
2,649.5
|
|
|
$
|
10.8
|
|
|
—
|
%
|
FSS International
|
|
953.1
|
|
|
913.0
|
|
|
40.1
|
|
|
4
|
%
|
|||
Uniform
|
|
651.9
|
|
|
402.6
|
|
|
249.3
|
|
|
62
|
%
|
|||
|
|
$
|
4,265.3
|
|
|
$
|
3,965.1
|
|
|
$
|
300.2
|
|
|
8
|
%
|
|
|
|
|||||||||||||
|
|
Three Months Ended
|
|
Change
|
|||||||||||
Operating Income by Segment
|
|
December 28, 2018
|
|
December 29, 2017
|
|
$
|
|
%
|
|||||||
FSS United States
|
|
$
|
363.7
|
|
|
$
|
180.1
|
|
|
183.6
|
|
|
102
|
%
|
|
FSS International
|
|
11.5
|
|
|
43.9
|
|
|
(32.4
|
)
|
|
(74
|
)%
|
|||
Uniform
|
|
52.7
|
|
|
44.5
|
|
|
8.2
|
|
|
18
|
%
|
|||
Corporate
|
|
(54.5
|
)
|
|
(51.6
|
)
|
|
(2.9
|
)
|
|
6
|
%
|
|||
|
|
$
|
373.4
|
|
|
$
|
216.9
|
|
|
$
|
156.5
|
|
|
72
|
%
|
•
|
growth in all of our reportable segments;
|
•
|
growth due to the Avendra and AmeriPride acquisitions (approximately 5%); and
|
•
|
the adoption of the new revenue recognition standard as certain fees previously recognized as a reduction to “Cost of services provided,” are now recognized in “Revenue" (approximately 2%); which more than offset
|
•
|
the divestiture of HCT (approximately -2%); and
|
•
|
the negative impact of foreign currency translation (approximately -1%).
|
|
|
Three Months Ended
|
||||||||||||
|
|
December 28, 2018
|
|
December 29, 2017
|
||||||||||
Cost of services provided
|
|
$
|
|
% of Revenue
|
|
$
|
|
% of Revenue
|
||||||
FSS United States
|
|
$
|
2,332.2
|
|
|
88
|
%
|
|
$
|
2,350.7
|
|
|
89
|
%
|
FSS International
|
|
920.4
|
|
|
97
|
%
|
|
849.0
|
|
|
93
|
%
|
||
Uniform
|
|
541.8
|
|
|
83
|
%
|
|
322.6
|
|
|
80
|
%
|
||
|
|
$
|
3,794.4
|
|
|
89
|
%
|
|
$
|
3,522.3
|
|
|
89
|
%
|
|
|
Three Months Ended
|
||||
Cost of services provided components
1
|
|
December 28, 2018
|
|
December 29, 2017
|
||
Food and support service costs
|
|
28
|
%
|
|
27
|
%
|
Personnel costs
|
|
46
|
%
|
|
46
|
%
|
Other direct costs
|
|
26
|
%
|
|
27
|
%
|
|
|
100
|
%
|
|
100
|
%
|
•
|
a gain from the divestiture of the HCT business (approximately $157.3 million);
|
•
|
income relating to the recovery of our investment (possessory interest) at one of the National Park Service ("NPS") sites in the
FSS United States segment (approximately $16.2 million); and
|
•
|
an increase in profit related to the acquisitions of Avendra and AmeriPride and lower merger and integration costs (approximately $10.8 million); partially offset by
|
•
|
an increase in severance and consulting costs related to streamlining initiatives (approximately $20.3 million); and
|
•
|
an increase in the loss related to the change in fair value of certain gasoline and diesel agreements (approximately$10.8 million).
|
|
Three Months Ended
|
Change
|
|||||||
|
December 28, 2018
|
|
December 29, 2017
|
%
|
|||||
Business & Industry
|
$
|
399.9
|
|
|
$
|
386.6
|
|
3
|
%
|
Education
|
1,016.3
|
|
|
1,003.9
|
|
1
|
%
|
||
Healthcare
|
263.3
|
|
|
322.7
|
|
(18
|
)%
|
||
Sports, Leisure & Corrections
|
594.3
|
|
|
565.3
|
|
5
|
%
|
||
Facilities & Other
|
386.5
|
|
|
371.0
|
|
4
|
%
|
||
|
$
|
2,660.3
|
|
|
$
|
2,649.5
|
|
—
|
%
|
•
|
an increase in Business & Industry sector revenue resulting from base business growth and net new business;
|
•
|
an increase in Education sector revenue resulting from base business growth;
|
•
|
an increase in Sports, Leisure & Corrections sector revenue resulting from base business growth and net new business; and
|
•
|
an increase in Facilities & Other sector revenue resulting primarily from acquisitions; which more than offset
|
•
|
a decrease in Healthcare sector revenue resulting from the divestiture of HCT (approximately -18%), partially offset by base business growth.
|
•
|
a gain from the divestiture of the HCT business (approximately $157.3 million);
|
•
|
income relating to the recovery of our investment (possessory interest) at one of the NPS sites within our Sports, Leisure & Corrections sector
(approximately $16.2 million);
|
•
|
an increase in profit related to the acquisition of Avendra; and
|
•
|
profit growth in the Education sector; which more than offset
|
•
|
an increase in duplicate rent charges to build out and ready our new headquarters while occupying our previous headquarters, impairment costs incurred while exiting our previous headquarters and moving costs associated with the relocation to the new headquarters (approximately $5.0 million); and
|
•
|
an increase in severance charges related to streamlining initiatives (approximately $3.5 million).
|
•
|
revenue growth across regions; and
|
•
|
revenue growth due to the consolidation of a joint venture (approximately 3%); partially offset by
|
•
|
the negative impact of foreign currency translation (approximately -6%).
|
•
|
an increase in severance costs related to streamlining initiatives (approximately $17.9 million);
|
•
|
closing costs related to the exit of a business (approximately $2.0 million);
|
•
|
the negative impact of foreign currency translation (approximately -$2.1 million); and
|
•
|
an increase in personnel costs and new business start-up costs.
|
•
|
an increase in profit related to the acquisition of AmeriPride; and
|
•
|
an increase in profit within our legacy uniform rental business; which more than offset
|
•
|
an increase in merger and integration related costs from the AmeriPride acquisition (approximately $3.6 million); and
|
•
|
income in the prior year under our casualty insurance program from prior years' loss experience that were favorable (approximately $3.4 million).
|
•
|
an increase in the loss related to the change in fair value of certain gasoline and diesel agreements (approximately$10.8 million);
|
•
|
banker fees related to the divestiture of Healthcare Technologies (approximately $6.1 million); and
|
•
|
closing costs related to the move to the Company's new headquarters (approximately $1.6 million); partially offset by
|
•
|
a decrease in acquisition related costs from the Avendra and AmeriPride acquisitions (approximately $13.5 million); and
|
•
|
lower consulting costs related to streamlining initiatives ($1.6 million).
|
|
Three Months Ended
|
||||||
|
December 28, 2018
|
|
December 29, 2017
|
||||
Net cash used in operating activities
|
$
|
(207.4
|
)
|
|
$
|
(311.4
|
)
|
Net cash provided by (used in) investing activities
|
194.2
|
|
|
(1,442.8
|
)
|
||
Net cash provided by financing activities
|
48.1
|
|
|
1,701.1
|
|
•
|
Accrued expenses were less of a use of cash primarily due to the timing of one-time payments made in the first quarter of fiscal 2018 for certain liabilities assumed related to the Avendra acquisition and from lower accrued payroll and related expenses payments, including incentive compensation; and
|
•
|
Accounts receivable were a greater use of cash due to the timing of collections and revenue growth;
|
•
|
an increase in funding under the Receivables Facility ($390.0 million); and
|
•
|
a repayment of borrowings on term loans and the revolving credit facility ($280.0 million, which includes $200.0 million of optional prepayments).
|
|
Three Months Ended
|
|
Three Months Ended
|
|
Three Months Ended
|
|
Three Months Ended
|
|
Twelve Months Ended
|
||||||||||
(in millions)
|
December 28, 2018
|
|
September 28, 2018
|
|
June 29, 2018
|
|
March 30, 2018
|
|
December 28, 2018
|
||||||||||
Net income attributable to ASI stockholder
|
$
|
250.7
|
|
|
$
|
175.4
|
|
|
$
|
72.6
|
|
|
$
|
27.6
|
|
|
$
|
526.3
|
|
Interest and other financing costs, net
|
83.0
|
|
|
92.5
|
|
|
91.2
|
|
|
94.2
|
|
|
360.9
|
|
|||||
Provision for income taxes
|
39.7
|
|
|
14.3
|
|
|
24.1
|
|
|
14.7
|
|
|
92.8
|
|
|||||
Depreciation and amortization
|
150.7
|
|
|
152.6
|
|
|
156.9
|
|
|
152.9
|
|
|
613.1
|
|
|||||
Share-based compensation expense
(1)
|
18.6
|
|
|
19.8
|
|
|
34.8
|
|
|
17.1
|
|
|
90.3
|
|
|||||
Unusual or non-recurring (gains) and losses
(2)
|
(157.3
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(157.3
|
)
|
|||||
Pro forma EBITDA for equity method investees
(3)
|
3.9
|
|
|
3.4
|
|
|
2.9
|
|
|
4.0
|
|
|
14.2
|
|
|||||
Pro forma EBITDA for certain transactions
(4)
|
(7.3
|
)
|
|
(18.0
|
)
|
|
(3.0
|
)
|
|
10.1
|
|
|
(18.2
|
)
|
|||||
Other
(5)
|
59.9
|
|
|
25.7
|
|
|
14.9
|
|
|
83.4
|
|
|
183.9
|
|
|||||
Covenant Adjusted EBITDA
|
$
|
441.9
|
|
|
$
|
465.7
|
|
|
$
|
394.4
|
|
|
$
|
404.0
|
|
|
$
|
1,706.0
|
|
(1)
|
Represents share-based compensation expense resulting from the application of accounting for stock options, restricted stock units, performance stock, performance stock units, and deferred stock unit awards (see Note 10
to the condensed consolidated financial statements
).
|
(2)
|
Represents the gain from the divestiture of Healthcare Technologies.
|
(3)
|
Represents our estimated share of EBITDA, primarily from our AIM Services Co., Ltd. equity method investment, not already reflected in our Net income attributable to ASI stockholder. EBITDA for this equity method investee is calculated in a manner consistent with consolidated Covenant Adjusted EBITDA but does not represent cash distributions received from this investee.
|
(4)
|
Represents the annualizing of net EBITDA from acquisitions and divestitures made during the period.
|
(5)
|
Other for the twelve months ended
December 28, 2018
includes organizational streamlining initiatives ($58.5 million),
the impact of the change in fair value related to certain gasoline and diesel agreements ($10.5 million loss), expenses related to merger and integration related charges ($67.4 million), property and other asset write-downs related to a
joint venture liquidation and related acquisition ($7.5 million),
duplicate rent charges, moving costs, opening costs to build out and ready the Company's new headquarters while occupying its existing headquarters and closing costs ($14.3 million), banker fees and other charges related to the sale of Healthcare Technologies ($9.9 million), certain environmental charges ($5.0 million), the impact of hyperinflation in Argentina ($3.8 million) and other miscellaneous expenses.
|
|
Covenant
Requirements |
|
Actual
Ratios |
Consolidated Secured Debt Ratio
(1)
|
5.125x
|
|
2.14
|
Interest Coverage Ratio (Fixed Charge Coverage Ratio)
(2)
|
2.000x
|
|
4.92
|
(1)
|
The Credit Agreement requires ASI to maintain a maximum Consolidated Secured Debt Ratio, defined as consolidated total indebtedness secured by a lien to Covenant Adjusted EBITDA, of
5.125x
. Consolidated total indebtedness secured by a lien is defined in the Credit Agreement as total indebtedness consisting of debt for borrowed money, capital leases, debt in respect of sale-leaseback transactions, disqualified and preferred stock and advances under the Receivables Facility secured by a lien reduced by the amount of cash and cash equivalents on the consolidated balance sheet that is free and clear of any lien. Non-compliance with the maximum Consolidated Secured Debt Ratio could result in the requirement to immediately repay all amounts outstanding under our Credit Agreement, which, if ASI's lenders under the Credit Agreement (other than the lenders in respect of ASI's U.S. Term Loan B, which lenders do not benefit from the maximum Consolidated Secured Debt Ratio covenant) failed to waive any such default, would also constitute a default under the indentures governing our senior notes.
|
(2)
|
Our Credit Agreement establishes an incurrence-based minimum Interest Coverage Ratio, defined as Covenant Adjusted EBITDA to consolidated interest expense, the achievement of which is a condition for us to incur additional indebtedness and to make certain restricted payments. If we do not maintain this minimum Interest Coverage Ratio calculated on a pro forma basis for any such additional indebtedness or restricted payments, we could be prohibited from being able to incur additional indebtedness, other than the incremental capacity provided for under the Credit Agreement and pursuant to specified exceptions, and make certain restricted payments, other than pursuant to certain exceptions. The minimum Interest Coverage Ratio is
2.000x
for the term of the Credit Agreement. Consolidated interest expense is defined in the Credit Agreement as consolidated interest expense excluding interest income, adjusted for acquisitions and dispositions, further adjusted for certain non-cash or nonrecurring interest expense and our estimated share of interest expense from one equity method investee.The indentures governing our senior notes include a similar requirement which is referred to as a Fixed Charge Coverage Ratio.
|
|
|
(a)
|
|
(b)
|
|
(c)
|
|
(d)
|
||||||
Period
|
|
Total Number of Shares (or Units) Purchased
|
|
Average Price Paid per Share (or Unit)
|
|
Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs
(1)
|
|
Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
(1)
|
||||||
Month 1
September 29, 2018 - October 26, 2018
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
$
|
125,600,000
|
|
|
Month 2
October 27, 2018 - November 23, 2018 (2) |
|
145,824
|
|
|
$
|
35.74
|
|
|
N/A
|
|
|
N/A
|
|
|
Month 3
November 24, 2018 - December 28, 2018 |
|
1,604,621
|
|
|
$
|
31.16
|
|
|
1,604,621
|
|
|
$
|
75,600,000
|
|
Total
|
|
1,750,445
|
|
|
$
|
31.54
|
|
|
1,604,621
|
|
|
$
|
75,600,000
|
|
(1)
|
On February 7, 2017, we announced a share repurchase program allowing us to repurchase up to $250.0 million of our common stock, which expired February 1, 2019.
|
(2)
|
Consists of shares withheld to pay taxes in connection with the vesting of performance restricted stock granted under the Company’s Amended and Restated 2013 Stock Incentive Plan.
|
1.
|
Election of each of the following 10 director nominees to the Company’s Board of Directors to serve until the Company’s 2020 Annual Meeting of Shareholders or until his or her respective successor has been duly elected and qualified:
|
Nominees for Director
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
||||
Eric J. Foss
|
205,498,045
|
|
12,619,241
|
|
1,097,105
|
|
4,744,631
|
|
Pierre-Olivier Beckers-Vieujant
|
211,877,319
|
|
7,278,654
|
|
58,418
|
|
4,744,631
|
|
Lisa G. Bisaccia
|
199,517,805
|
|
19,638,326
|
|
58,260
|
|
4,744,631
|
|
Calvin Darden
|
199,822,311
|
|
19,333,816
|
|
58,264
|
|
4,744,631
|
|
Richard W. Dreiling
|
199,184,345
|
|
19,971,627
|
|
58,419
|
|
4,744,631
|
|
Irene M. Esteves
|
211,545,495
|
|
7,611,073
|
|
57,823
|
|
4,744,631
|
|
Daniel J. Heinrich
|
211,180,592
|
|
7,975,179
|
|
58,620
|
|
4,744,631
|
|
Patricia B. Morrison
|
212,197,305
|
|
6,958,754
|
|
58,332
|
|
4,744,631
|
|
John A. Quelch
|
211,877,333
|
|
7,278,433
|
|
58,625
|
|
4,744,631
|
|
Stephen I. Sadove
|
197,608,376
|
|
21,547,195
|
|
58,820
|
|
4,744,631
|
|
2.
|
Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending September 27, 2019:
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
221,238,623
|
2,679,625
|
40,774
|
—
|
3.
|
Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement for the 2019 Annual Meeting of Shareholders filed on December 21, 2018:
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
122,251,737
|
96,905,074
|
57,580
|
4,744,631
|
|
|
|
|
Aramark
|
||
|
|
|
|
|||
|
|
|
|
By:
|
|
/s/ STEPHEN P. BRAMLAGE, JR.
|
|
|
|
|
Name:
|
|
Stephen P. Bramlage, Jr.
|
|
|
|
|
Title:
|
|
Executive Vice President and Chief Financial Officer
|
Exhibit No.
|
|
|
Description
|
10.1
|
|
|
|
10.2
|
|
|
|
31.1
|
|
|
|
31.2
|
|
|
|
32.1
|
|
|
|
101
|
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
No Customers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|